Next Article in Journal
Asiatic Acid, Extracted from Centella asiatica and Induces Apoptosis Pathway through the Phosphorylation p38 Mitogen-Activated Protein Kinase in Cisplatin-Resistant Nasopharyngeal Carcinoma Cells
Previous Article in Journal
The Genetics of Thoracic Aortic Aneurysms and Dissection: A Clinical Perspective
Article

Structure–Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy

1
Eötvös Loránd University (ELTE), Faculty of Science, Institute of Chemistry, Budapest 1117, Hungary
2
MTA-ELTE Research Group of Peptide Chemistry, Budapest, Hungary, Budapest 1117, Hungary
3
Research Centre for Natural Sciences, Institute of Enzymology, Hungarian Academy of Sciences, Budapest 1117, Hungary
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Biomolecules 2020, 10(2), 183; https://doi.org/10.3390/biom10020183
Received: 20 December 2019 / Revised: 17 January 2020 / Accepted: 23 January 2020 / Published: 25 January 2020
Human epidermal growth factor (HER2) is a transmembrane tyrosine kinase receptor that is frequently overexpressed in breast cancer. Its increased level prognoses a poor patient outcome and a high mortality rate. Despite the widening spectrum of therapies that are becoming available to treat HER2+ breast cancer, its side effects and resistance still make this protein a valuable object of research in targeted tumor therapy. The role of tumor-targeting peptides has become more and more prominent in the last few decades due to their simple synthesis and pharmakokinetic properties. Here, we examine two fluorescently-labeled HER2-specific peptides and their combined analogues that are developed to target the extracellular region of HER2. The peptides are investigated on breast cancer cell lines with different HER2 expression profiles. Moreover, their extracellular localization and specificity are confirmed by flow cytometry and confocal microscopy. Therefore, a new, combined HER2 binding conjugate is obtained that interacts with HER2-overexpressing cells with high affinity and specificity. Furthermore, secondary structure prediction reveals that the α-helical content of the peptides is associated with their receptor recognition. This highly specific conjugate can be used as a starting point for diagnostical or drug-targeting purposes in upcoming studies. View Full-Text
Keywords: HER2; breast cancer; targeting peptide; targeted tumor therapy; HER2 diagnosis HER2; breast cancer; targeting peptide; targeted tumor therapy; HER2 diagnosis
Show Figures

Graphical abstract

MDPI and ACS Style

Biri-Kovács, B.; Adorján, A.; Szabó, I.; Szeder, B.; Bősze, S.; Mező, G. Structure–Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy. Biomolecules 2020, 10, 183. https://doi.org/10.3390/biom10020183

AMA Style

Biri-Kovács B, Adorján A, Szabó I, Szeder B, Bősze S, Mező G. Structure–Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy. Biomolecules. 2020; 10(2):183. https://doi.org/10.3390/biom10020183

Chicago/Turabian Style

Biri-Kovács, Beáta, Afrodité Adorján, Ildikó Szabó, Bálint Szeder, Szilvia Bősze, and Gábor Mező. 2020. "Structure–Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy" Biomolecules 10, no. 2: 183. https://doi.org/10.3390/biom10020183

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop